We describe a patient with systemic lupus erythematosus (SLE) who exhibited severe cutaneous involvement characterized by the simultaneous presence of acute, subacute and discoid lesions in association with anti-Sl antibodies. After she failed to respond to chloroquine, medium to low dose steroids, steroid pulses, retinoids and cyclophosphamide, the patient was treated with Dapsone and a dramatic improvement in the cutaneous lesions was seen after only one month.
Dubois EL . Dubois' Lupus Erythematosus, 5th edn, Wallace DJ , Hahn BH (eds). 1997, pp 693–721.
2.
Vitali C , Doria A , Tincani A et al. International survey on the management of patients with SLE. I. General data on the participating center and the results of a questionnaire regarding mucocutaneous involvement . Clin Exp Rheumatol1996; 14 (Suppl 16): S17–S22 .
3.
Rothe MJ , Kerdel FA . Treatment of cutaneous lupus erythematosus . Lupus1992; 1: 351–356 .
Duna GF , Cash JM . Treatment of refractory cutaneous lupus erythematosus . Rheum Dis Clin North Am1995; 21: 99–115 .
6.
Hall RP , Lawley TJ , Smith HR et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy . Ann Intern Med1982; 97: 165–170 .
7.
Holtman JH , Neustadt DH , Klein J , Callen JP . Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency . J Rheumatol1990; 17: 1222–1225 .
8.
Fenton DA , Black MM . Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus . Clin Exp Dermatol1986; 11: 102–103 .
9.
Bernstein RM , Morgan SH , Bunn CC et al. The SL autoantibody-antigen system: clinical and biochemical studies . Ann Rheum Dis1986; 5: 353–358 .
10.
Neri R , Bernacchi E , Mosca M et al. Are anti-Sl antibodies associated with more severe cutaneous involvement?Lupus1998; 7 (Suppl 1): S19-S19 .
